132 related articles for article (PubMed ID: 12091010)
1. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Fuchs FD
Lancet; 2002 Jun; 359(9324):2203; author reply 2203-4. PubMed ID: 12091010
[No Abstract] [Full Text] [Related]
2. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Hamon M
Lancet; 2002 Jun; 359(9324):2199-200; author reply 2203-4. PubMed ID: 12091003
[No Abstract] [Full Text] [Related]
3. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Cruickshank JM
Lancet; 2002 Jun; 359(9324):2200-1; author reply 2203-4. PubMed ID: 12091004
[No Abstract] [Full Text] [Related]
4. The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
Olsen MH; Wachtell K; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Lyle PA; Nieminen MS
J Hum Hypertens; 2006 Jun; 20(6):460-4. PubMed ID: 16572193
[No Abstract] [Full Text] [Related]
5. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
Ibsen H; Lindholm LH; Pedersen OL; Dahlöf B; Kjeldsen S
Ugeskr Laeger; 2003 Jan; 165(5):459-62. PubMed ID: 12599844
[TBL] [Abstract][Full Text] [Related]
6. Effects of losartan in hypertension without vascular disease.
Messerli FH
Ann Intern Med; 2004 Apr; 140(7):W29. PubMed ID: 15069010
[No Abstract] [Full Text] [Related]
7. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
[TBL] [Abstract][Full Text] [Related]
8. [To protect the hypertensive patient from complications. Blood pressure lowering is not equal to blood pressure lowering].
MMW Fortschr Med; 2003 Nov; 145(45):51. PubMed ID: 14712789
[No Abstract] [Full Text] [Related]
9. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
10. Summaries for patients. Benefits of losartan in patients with hypertension and left ventricular hypertrophy but no vascular disease.
Ann Intern Med; 2003 Aug; 139(3):I28. PubMed ID: 12899605
[No Abstract] [Full Text] [Related]
11. Losartan vs atenolol in prevention of stroke and cardiovascular disease.
Fournier A; Oprisiu R; Andrejak M; Fernandez L; Achard JM
JAMA; 2003 Feb; 289(6):700; author reply 701. PubMed ID: 12585946
[No Abstract] [Full Text] [Related]
12. Losartan vs atenolol in prevention of stroke and cardiovascular disease.
Messerli FH; Grossman E; Fournier A
JAMA; 2003 Feb; 289(6):700-1; author reply 701. PubMed ID: 12585945
[No Abstract] [Full Text] [Related]
13. Diuretics in the LIFE study.
Kato J; Eto T
Lancet; 2004 Jul 31-Aug 6; 364(9432):413; author reply 413-4. PubMed ID: 15288732
[No Abstract] [Full Text] [Related]
14. The LIFE Trial in 2004.
Beevers DG
J Hum Hypertens; 2004 Jun; 18(6):365. PubMed ID: 15153931
[No Abstract] [Full Text] [Related]
15. [Clinical hypertensiology: analysis of trials completed in 2001-2002].
Karpov IuA
Kardiologiia; 2002; 42(10):62-6. PubMed ID: 12494060
[No Abstract] [Full Text] [Related]
16. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Cockcroft JR; Brown MJ
Lancet; 2002 Jun; 359(9324):2202; author reply 2203-4. PubMed ID: 12091008
[No Abstract] [Full Text] [Related]
17. Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Ruwald AC; Westergaard B; Sehestedt T; Kjeldsen SE; Lindholm LH; Wachtell K; Devereux RB; Ibsen H; Nieminen MS; Dahlöf B; Olsen MH
J Hypertens; 2012 Jun; 30(6):1252-9. PubMed ID: 22499288
[TBL] [Abstract][Full Text] [Related]
18. [Kidney protection leads to heart protection, too].
MMW Fortschr Med; 2006 Aug; 148(33-34):57. PubMed ID: 16981393
[No Abstract] [Full Text] [Related]
19. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
[TBL] [Abstract][Full Text] [Related]
20. [Results from the LIFE study: promising effects of new hypertensive agents].
Nilsson P; Kahan T
Lakartidningen; 2002 Apr; 99(16):1792-4. PubMed ID: 12043477
[No Abstract] [Full Text] [Related]
[Next] [New Search]
